| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | -0.0024 | 0.9 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.0023 | 0.9 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.0033 | 0.9 |
| mRNA | BRD-A02303741:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0024 | 1 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.0032 | 1 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.0021 | 1 |